Get in-depth coverage of current and future trends in technology, and how they are shaping business, entertainment, communications, science, politics, and society.
…
continue reading
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!
Go offline with the Player FM app!
Urothelial Bladder Cancer | Oncology Today with Dr Neil Love: Management of Metastatic Urothelial Bladder Cancer (Companion Faculty Lecture)
MP4•Episode home
Manage episode 437155014 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:
- Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
- Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
- Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
- Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
- Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)
1346 episodes
MP4•Episode home
Manage episode 437155014 series 2530615
Content provided by Dr Neil Love. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Dr Neil Love or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Featuring a slide presentation and related discussion from Dr Michiel van der Heijden, including the following topics:
- Efficacy and safety data from the Phase III EV-302/KEYNOTE-A39 trial comparing enfortumab vedotin/pembrolizumab to chemotherapy for patients with previously untreated metastatic urothelial bladder cancer (mUBC) (0:00)
- Principal findings from the Phase III CheckMate 901 substudy of nivolumab in combination with chemotherapy and continued as monotherapy compared to chemotherapy alone as first-line treatment for cisplatin-eligible patients with mUBC (14:36)
- Key data from the Phase III THOR trial of erdafitinib for patients with relapsed mUBC and susceptible FGFR3 or FGFR2 genetic alterations (22:03)
- Long-term findings with sacituzumab govitecan for patients with progressive mUBC; emerging data from the Phase III TROPiCS-04 study (29:43)
- Outcomes observed in the cohort of patients with mUBC in the Phase II DESTINY-PanTumor02 trial of trastuzumab deruxtecan (36:19)
1346 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.